Arcturus Therapeutics saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an increase from 87 to 92.
How To Use Stock Charts To Stay Profitable And Protected
IBD's unique RS Rating identifies technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history shows that the best-performing stocks typically have an 80 or higher RS Rating at the beginning of a new price run.
Arcturus Therapeutics is not currently near a potential buying area. See if the stock goes on to form a promising consolidation that could launch a new move.
The company reported 0% earnings growth in the latest quarterly report, while sales growth came in at -43%.
Arcturus Therapeutics earns the No. 112 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
